ANAB

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

AnaptysBio Inc

NASDAQ | ANAB

34.00

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 23, 2025)

$941.29M

Market Cap

-

P/E Ratio

-4.39

EPS

$35.77

52 Week High

$12.21

52 Week Low

HEALTHCARE

Sector

ANAB Chart

Recent Chart
Price Action

ANAB Technicals

Tags:

ANAB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $91M
Total Revenue $91M
Cost Of Revenue $2.4M
Costof Goods And Services Sold $2.4M
Operating Income -$115M
Selling General And Administrative $42M
Research And Development $164M
Operating Expenses $206M
Investment Income Net -
Net Interest Income -$30M
Interest Income $20M
Interest Expense $50M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.4M
Income Before Tax -$145M
Income Tax Expense $3K
Interest And Debt Expense -
Net Income From Continuing Operations -$145M
Comprehensive Income Net Of Tax -
Ebit -$95M
Ebitda -$93M
Net Income -$145M

Revenue & Profitability

Earnings Performance

ANAB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $484M
Total Current Assets $432M
Cash And Cash Equivalents At Carrying Value $123M
Cash And Short Term Investments $123M
Inventory -
Current Net Receivables $41M
Total Non Current Assets $52M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $35M
Short Term Investments $262M
Other Current Assets $5.7M
Other Non Current Assets -
Total Liabilities $413M
Total Current Liabilities $45M
Current Accounts Payable $4M
Deferred Revenue -
Current Debt -
Short Term Debt $1.9M
Total Non Current Liabilities $368M
Capital Lease Obligations $16M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $16M
Other Current Liabilities $40M
Other Non Current Liabilities $353M
Total Shareholder Equity $71M
Treasury Stock -
Retained Earnings -$759M
Common Stock $30K
Common Stock Shares Outstanding $28M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$135M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.4M
Capital Expenditures $358K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $95M
Cashflow From Financing $127M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$456K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$145M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $91M
Total Revenue $91M
Cost Of Revenue $2.4M
Costof Goods And Services Sold $2.4M
Operating Income -$115M
Selling General And Administrative $42M
Research And Development $164M
Operating Expenses $206M
Investment Income Net -
Net Interest Income -$30M
Interest Income $20M
Interest Expense $50M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.4M
Income Before Tax -$145M
Income Tax Expense $3K
Interest And Debt Expense -
Net Income From Continuing Operations -$145M
Comprehensive Income Net Of Tax -
Ebit -$95M
Ebitda -$93M
Net Income -$145M

ANAB News

ANAB Profile

AnaptysBio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing cutting-edge therapeutics targeting inflammatory diseases and immuno-oncology. Leveraging its proprietary antibody development platforms, the company is advancing a diverse pipeline of candidates through clinical trials, aiming to address significant unmet medical needs across various therapeutic areas. With a strong emphasis on scientific innovation and a commitment to delivering transformative therapies, AnaptysBio presents a compelling investment opportunity for institutional investors seeking high-growth potential in the biotechnology landscape.

YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
BURU
-5.27%
$0.34
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
INTC
+3.35%
$38.15
MSAI
+101.73%
$1.35
ADAP
-3.44%
$0.07
AAL
+5.62%
$12.77
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
BITF
+4.39%
$4.11
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
IONQ
+7.06%
$59.37
DNN
+0.18%
$2.72
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
JOBY
+1.29%
$15.67
BBD
+1.51%
$3.35
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
ADD
-25.47%
$0.05
BTG
+0.38%
$5.23
VLY
+4.24%
$10.56
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
PFE
-0.20%
$24.67
TNGX
-12.24%
$7.60
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
UUUU
-6.50%
$21.26
CIFR
+7.10%
$17.25
WBD
+3.50%
$21.25
ONDS
+5.56%
$7.11
AMZN
+1.44%
$221.09
HPE
+0.43%
$23.19
NIO
+0.73%
$6.89
IREN
+7.77%
$55.86
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
PBR
+0.93%
$11.84
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
RIVN
+1.31%
$13.09
BAC
+1.29%
$51.76
BTE
+5.28%
$2.39
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.58%
$7.78
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
NAKA
+10.41%
$0.79
SMR
+8.17%
$37.56
YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
BURU
-5.27%
$0.34
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
INTC
+3.35%
$38.15
MSAI
+101.73%
$1.35
ADAP
-3.44%
$0.07
AAL
+5.62%
$12.77
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
BITF
+4.39%
$4.11
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
IONQ
+7.06%
$59.37
DNN
+0.18%
$2.72
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
JOBY
+1.29%
$15.67
BBD
+1.51%
$3.35
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
ADD
-25.47%
$0.05
BTG
+0.38%
$5.23
VLY
+4.24%
$10.56
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
PFE
-0.20%
$24.67
TNGX
-12.24%
$7.60
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
UUUU
-6.50%
$21.26
CIFR
+7.10%
$17.25
WBD
+3.50%
$21.25
ONDS
+5.56%
$7.11
AMZN
+1.44%
$221.09
HPE
+0.43%
$23.19
NIO
+0.73%
$6.89
IREN
+7.77%
$55.86
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
PBR
+0.93%
$11.84
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
RIVN
+1.31%
$13.09
BAC
+1.29%
$51.76
BTE
+5.28%
$2.39
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.58%
$7.78
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
NAKA
+10.41%
$0.79
SMR
+8.17%
$37.56
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.